Over the last decade, the emergence of anticancer immunotherapies, especially immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), or PD-ligand 1(PD-L1) to boost tumor-specific T lymphocyte immunity, has opened a brand new chapter for treatment of multiple histological types of malignancies with durable responses and unsurpassed clinical efficacy [1]. This evidence concerns the gene CD274 and neoplasm.